Seeking Alpha

Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating...

Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating on revenue. Net earnings actually fell 2.7% Y/Y, due largely to the company's preparations to launch its new multiple sclerosis drug BG-12, which masked revenue growth from its existing MS treatment. The company also boosted its FY13 revenue growth expectations to 10%. Analysts are looking for a 9% rise to $5.98B.
Comments (1)
  • The writer is obviously biased. I do not think a 10% rise in revenue is a "slight" one. Get a job if you can't figure things out correctly and accurately.
    28 Jan 2013, 04:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)